KOC CTC SAW MicroLab

In the era of precision medicine, hospitals need to integrate and utilize complex sensor and diagnostic equipment data. However, low interoperability and reliance on manual analysis by medical staff lead to inefficiencies. Furthermore, there is a lack of integrated data analysis to aid in optimal treatment decisions for each patient, limiting personalized care.

The KOC CTC SAW MicroLab integrates various diagnostic sensors (e.g., SAW-based biosensors, optical sensors, etc.) into a single platform and provides disease prediction and prevention functions by analyzing real-time clinical data with AI algorithms [41].

For example, it simultaneously measures biomarkers and biosignals in the blood to calculate complex disease risks, allowing doctors to use the results directly in treatment decisions. With remote connectivity, healthcare professionals can check and consult MicroLab data from remote locations.

In summary, the fusion of multi-sensors and AI to enable data-driven, patient-specific treatment is innovative. It also optimizes healthcare operational efficiency by automating manual interpretation, saving healthcare professionals time.

Major hospitals and specialized clinics (B2B) are the main customers. Government medical institutions or research institutes can also purchase and use it for medical big data analysis.

In line with the digital transformation trend in the medical field, there are potential opportunities in domestic and international hospital markets.

Korea Optron is a sensor specialist company with industrial applications, but this product is an entry into the medical field, so regulatory approval and securing trust in the medical community are key. If successful, it can be expanded into other diagnostic areas (such as cancer diagnosis) as a smart healthcare platform.

While the technology concept is advanced, some found it difficult to grasp the specifics. Although it gained attention with the CES award, the actual demo lacked concreteness, leading to many opinions that "the ambition is great, but it is still in the research stage."

On the positive side, the attempt to integrate medical AI was highly evaluated, while on the negative side, the lack of clear positioning as a commercial product was pointed out.